Long-Term Safety of Simufilam for Alzheimer's Disease
Trial Summary
What is the purpose of this trial?
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
Research Team
James Kupiec, MD
Principal Investigator
Cassava Sciences, Inc.
Eligibility Criteria
This trial is for people who have Alzheimer's Disease and were part of earlier Phase 3 trials called RETHINK-ALZ or REFOCUS-ALZ. Participants need a study partner and must still show symptoms consistent with Alzheimer's. Those in full-time nursing care, with other significant neurological conditions, unstable medical issues, or serious psychiatric diagnoses besides Alzheimer's cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Baseline assessments conducted using clinical and laboratory assessments from the Week 76 (REFOCUS-ALZ) or Week 52 (RETHINK-ALZ) End-of-Treatment visit
Treatment
Participants receive simufilam 100 mg oral tablet, twice daily, with safety assessments every 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Simufilam
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cassava Sciences, Inc.
Lead Sponsor